http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020225302-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8a143113a8426bd57def2ea84d70df56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_01294c99918b697c2a6fde9db6374f6a |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-382 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-84 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-84 |
| filingDate | 2020-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_83544a2f972ccab5a8a85376bbdbaea2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf3b0e986537fb9cbef4ff78d0fc1526 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d20265efb60c6ecb3755e52747bf6241 |
| publicationDate | 2020-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2020225302-A1 |
| titleOfInvention | Cystic fibrosis urine test |
| abstract | The present invention relates to a method of determining the effectiveness of a compound in a subject for treatment of cystic fibrosis comprising the steps of a) determining a first excretion level of bicarbonate in a first urine sampling obtained from a subject having cystic fibrosis; where said first urine sampling has been obtained prior to said subject has been treated with a compound for treatment of cystic fibrosis; b) determining a second excretion level of bicarbonate in a second urine sampling from said subject; where said second urine sampling is obtained after said subject has been treated with said compound for a predetermined time period; and c) determining the effectiveness of the compound against cystic fibrosis by comparing said first excretion level of bicarbonate to said second excretion level of bicarbonate; wherein said compound is considered as effective if said second excretion level of bicarbonate is above said first excretion level of bicarbonate and said compound is considered ineffective if said second excretion level of bicarbonate is below or at the same excretion level as said first excretion level of bicarbonate. The present invention also relates to a method for sub-categorizing cystic fibrosis. |
| priorityDate | 2019-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 122.